From Prediction to Reality: How the BIO2025 Workforce Trends Are Playing Out in 2026

When Vector CEO Neil Kelly attended the 2025 BIO International Convention in Boston, he returned with a clear warning for life sciences leaders: workforce strategy was no longer a support function — it had become a business imperative. The BIO2025 Annual Review identified nine defining trends reshaping how companies attract, develop, and retain talent across biopharma, CDMO, and CRO environments.

Less than a year on, those predictions aren't just holding up. They're accelerating.

Here's how each major theme from our BIO2025 Annual Review is playing out in 2026 — and what that means for your hiring strategy right now.

1. AI Literacy: From Operational Reality to Survival Requirement

BIO2025 predicted: AI would move from hype to operational reality across every function — from regulatory writing to patient recruitment — and that "AI literacy" would become a baseline requirement, not a specialist skill.

What's happening in 2026: The prediction has proven conservative. AI and machine learning are now treated as core scientific infrastructure across leading biopharma organisations. Eli Lilly, for instance, has partnered with NVIDIA to build dedicated supercomputing capability for molecular simulations — a signal that AI investment has moved well beyond pilot programmes. Across the sector, nearly half of industry executives now rate digital transformation and AI as their top strategic priority.

The talent market reflects this shift acutely. Demand for professionals who combine domain expertise with data fluency — what the industry is calling "hybrid" or "domain-aware" talent — is outpacing supply in every major hiring geography. Companies that failed to invest in AI upskilling during 2024 and 2025 are now finding themselves unable to staff the very functions they need to compete.

ManpowerGroup's Healthcare and Life Sciences World of Work Outlook 2026 found that 77% of employers globally are struggling to find the skilled talent they need — making life sciences the most talent-scarce industry in the world. Generative AI investment is intensifying the gap: 60% of life sciences executives plan to increase generative AI spend across their value chains, yet only 19% say they are fully leveraging AI in their hiring processes.

What this means for talent leaders: Digital fluency and prompt engineering proficiency need to be embedded into job descriptions, onboarding programmes, and L&D roadmaps across every function — not just data science. Recruiting AI-literate scientists, bioinformaticians, and digital process engineers is now a board-level priority.

2. Partnerships as Infrastructure: Networked Organisations Are the New Normal

BIO2025 predicted: Cross-border alliances and CDMO networks would reshape how companies think about capability, requiring talent that can operate fluidly across institutional boundaries and manage shared accountability.

What's happening in 2026: The shift toward networked, partnership-led organisations has continued at pace. AstraZeneca's announced investment of $570 million in talent expansion in Toronto for global clinical trials is one example of a broader trend: major players are building distributed capability across geographies rather than concentrating all expertise internally.

At the same time, pressure to localise manufacturing and reduce reliance on overseas suppliers is accelerating. In the EU, more than 80% of active pharmaceutical ingredients are currently sourced from China and India, driving policy responses — including the proposed Critical Medicines Act — that will require companies to rapidly build local manufacturing partnerships and talent ecosystems.

For CDMOs and CROs, this creates significant growth opportunity — but only for those who can scale people alongside process. The challenge articulated at BIO2025 by Emerald Clinical CEO Mary Gunn — "we have the platform, we have demand, but we need to scale people" — remains one of the defining tensions in the sector.

What this means for talent leaders: HR and talent acquisition leaders must prioritise professionals with experience managing multi-organisation collaborations, outsourced functions, and client-facing technical roles. Building internal integration capability — teams who understand both the science and the external partner landscape — is increasingly a competitive differentiator.

3. Cell & Gene Therapy Talent Crunch: The Bottleneck Gets Tighter

BIO2025 predicted: An acute shortage of skilled workers in CGT manufacturing, viral vector processing, and analytics would become a major bottleneck as small and mid-size innovators scaled.

What's happening in 2026: Investment in cell and gene therapies reached $15.2 billion in 2025 — 30% growth compared to 2023 — and the CGT market is now projected to grow at a compound annual growth rate of 15.62%, reaching $14.68 billion by 2034. Broader adoption of CAR-T therapies, CRISPR-based gene editing, and off-the-shelf cell therapies is creating demand for manufacturing and quality talent that the sector is structurally unable to meet.

The challenge identified in our BIO2025 report — the transition from bespoke academic science to scalable industrial operations — remains the defining tension for the CGT sector in 2026. Companies built around early-stage clinical development are now being asked to operate with the rigour and repeatability of mature commercial biopharma, and the talent pipelines to support that transition simply do not yet exist at the scale required.

Urgent shortages persist in GMP manufacturing, quality control, CMC regulatory, and viral vector development roles. Professionals with experience navigating scale-up, regulatory inspections, and sustained GMP operations command a significant premium — and are in chronically short supply across all major biotech hubs.

What this means for talent leaders: Early-access talent pipelines through academic partnerships and apprenticeships targeting CGT-specific disciplines are no longer optional — they are the only structural solution to a shortage that cannot be resolved through competitive compensation alone. Cross-training professionals from adjacent disciplines into CGT roles, and offering competitive relocation packages for viral vector specialists, remain the most effective near-term levers.

4. Competitive Talent Geographies: The Regional Arms Race Continues

BIO2025 predicted: States and regions would compete aggressively to attract biotech companies and workforces, with Massachusetts — having surpassed 140,000 life sciences jobs — and emerging hubs like the UAE leading a geographic reshaping of the talent landscape.

What's happening in 2026: The competitive geography thesis has played out globally. Boston/Cambridge, the San Francisco Bay Area, San Diego, and Basel continue to dominate as life sciences hiring powerhouses, with sustained hiring activity even as overall vacancy growth slows. Meanwhile, Asia-Pacific is rapidly emerging as a major life sciences R&D and manufacturing hub, with talent demand rising sharply for biologics manufacturing, GMP-compliant CDMO operations, and AI-driven research roles.

The US Biosecure Act — restricting biotech investment in entities deemed to be of concern — is accelerating the geographic reshaping of supply chains and manufacturing footprints. Companies that built dependencies on overseas manufacturing are actively building regional alternatives, creating localised hiring surges in North America and Europe.

Geopolitical uncertainty and trade disruption are compounding these dynamics. 65% of employers say global trade uncertainty is having a moderate or significant impact on their hiring decisions — and workforce planning is increasingly inseparable from site selection strategy.

What this means for talent leaders: Geographic labour market analysis must be embedded in site selection decisions. Companies expanding into new regions — whether driven by incentives, policy, or supply chain resilience — need to understand the local talent ecosystem before they commit capital. If you can't staff it, you can't run it.

5. Inclusion and Storytelling: Purpose-Driven Culture as a Recruitment Tool

BIO2025 predicted: Authentic storytelling and inclusive leadership would become business-critical talent levers, with early-career scientists and under-represented talent increasingly prioritising purpose-driven workplaces.

What's happening in 2026: With overall vacancy growth slowing and competition for roles intensifying, employer brand has emerged as one of the most powerful differentiators in the market. Candidates — particularly early-career researchers and scientists from under-represented backgrounds — are making decisions based on mission, culture, and impact alongside compensation.

Companies able to communicate a compelling Employee Value Proposition, built around real patient impact stories and authentic leadership, are consistently outperforming peers in both time-to-fill and quality-of-hire metrics. Investors are also increasingly scrutinising culture and DE&I outcomes as indicators of long-term organisational health.

For smaller biotech firms — unable to compete on compensation with large pharma — mission-led storytelling is often the only viable recruitment strategy for attracting purpose-motivated senior talent.

What this means for talent leaders: Employer brand investment is not a marketing expense. Refreshing your EVP to reflect genuine patient impact, empowering hiring managers to tell authentic culture stories, and auditing your onboarding experience against candidate expectations are all talent strategy priorities with direct commercial impact.

6. Science Advocacy as a Workforce Issue: The Stakes Have Risen

BIO2025 predicted: Science denial and federal disinvestment in public health research represented a serious threat — not just to public health, but to employment, production, and the innovation ecosystem.

What's happening in 2026: This warning has proven prescient. Federal funding volatility and shifting policy landscapes in the US are creating real uncertainty for academic and early-career researchers considering careers in life sciences. The threat to vaccine funding and public health research programmes — which support tens of thousands of jobs in states like Pennsylvania — is no longer hypothetical.

Workforce morale and scientific continuity are directly affected when institutional alignment with evidence-based science cannot be taken for granted. Organisations that have embedded science integrity into their employer brand and EVP — particularly those recruiting academic researchers — are better positioned to attract and retain talent during periods of political volatility.

What this means for talent leaders: Proactive communication about how your organisation is responding to policy shifts and funding risks is a retention tool. Equipping senior leaders with clear internal messaging that reinforces a pro-science, evidence-based culture is no longer optional — it is part of the employer brand.

7. Commercialisation as Retention: The Science Translator Is the New BD Rep

BIO2025 predicted: Companies that failed to bridge the gap between research and commercialisation would lose top scientific talent to organisations offering clearer career trajectories and the opportunity to see innovations through to impact.

What's happening in 2026: This trend has crystallised. The new generation of business development and commercial roles in life sciences demands what might be called "science translators with business fluency" — professionals who can explain a peptide to a founder, pitch a development timeline to a PE investor, and co-architect launch strategies with virtual biotechs. This is a profile that barely existed five years ago and is now one of the most sought-after in the sector.

At the same time, retaining senior scientists through later-stage development and commercialisation remains a critical challenge. Companies that offer clear cross-functional career paths — exposing technical talent to CMC, regulatory, and commercial functions — are demonstrating measurably better retention outcomes than those that keep scientists in narrow early-discovery roles.

What this means for talent leaders: Career architecture matters as much as compensation. Designing roles and progression pathways that retain scientists beyond early R&D, and advocating for internal mobility programmes that expose technical staff to commercial realities, are among the highest-ROI retention investments available to people leaders right now.

8. Public-Private Workforce Infrastructure: The Model Is Spreading

BIO2025 predicted: Proactive collaboration between industry and state leadership — exemplified by Governor Shapiro's creation of a life sciences-focused economic development office in Pennsylvania, and programmes like Massachusetts' MassBioEdge — would become a key differentiator for regions successfully scaling biotech clusters.

What's happening in 2026: The public-private workforce infrastructure model is becoming mainstream. The EU's Pharmaceutical Strategy for Europe — backed by more than €10 billion per year — is targeting the entire value chain from R&D to advanced therapies, with an explicit focus on regulatory harmonisation, talent development, and manufacturing resilience. The UK's Life Sciences Sector Plan similarly includes measures to strengthen clinical-trial capacity, accelerate manufacturing investment, and support digital and AI-enabled research infrastructure.

Regions with active co-investment in life sciences workforce infrastructure are demonstrating a measurable advantage in talent attraction and time-to-fill for strategic roles. Biotech companies choosing site locations based on cost or incentive alone — without factoring in the maturity of the local talent ecosystem — are learning an expensive lesson.

What this means for talent leaders: HR and talent acquisition leaders should be active participants in regional workforce strategy conversations, not passive recipients of location decisions made by finance and operations. Building partnerships with local governments, training providers, and community colleges to co-develop talent pipelines is a long-term investment with compounding returns.

The Overarching Narrative: Workforce Strategy Is Business Strategy

If BIO2025 planted a flag — that workforce readiness was becoming a direct driver of enterprise value — then 2026 is the year that thesis has moved from conference debate to boardroom reality.

The companies winning in this environment are not necessarily those with the strongest pipelines. They are the ones that saw these talent trends coming, invested early, and built the organisational capability to attract and retain the people who make pipelines real.

BIO2026 in San Diego will deepen the conversation around cross-border workforce mobility, AI-driven clinical operations, onshore CGT manufacturing capacity, and what it means to build the next generation of scientific leaders during a period of geopolitical tension and funding instability.

The question for every executive reading this is not whether these trends affect your organisation. It is whether your talent strategy is keeping pace.

About Vector

Vector is a specialist talent consultancy supporting growing CDMOs, CROs, and biopharma companies. Our mission is to help clients build and develop the high-performing teams needed to improve patients' lives and get cutting-edge science to market faster.

To discuss your talent strategy, contact Neil Kelly, CEO & Founder: neil@vectorta.com | +44 7801 547271 | www.vectorta.com

Keywords: life sciences talent 2026, biopharma workforce strategy, CDMO recruitment, cell and gene therapy talent shortage, AI literacy life sciences, biotech hiring trends, CGT manufacturing talent, science workforce planning, life sciences employer brand, BIO2025 BIO2026

‍